ESMO 2025: Data, Decisions, and the Future of Oncology
The ESMO Congress 2025 brought together leading clinicians, researchers, and pharmaceutical innovators to discuss the future of cancer treatment.
Across five days in Berlin, the event showcased late-stage clinical data and strategic insights, reaffirming ESMO's status as a defining moment in the oncology calendar.
- Next-generation immunotherapies
- Antibody-drug conjugates (ADCs)
- AI-driven precision medicine
Advances in tumor-agnostic therapies and novel checkpoint inhibitors are reshaping expectations for patient outcomes, particularly in lung, breast, and gastrointestinal cancers.
No specific quote available.
Author's summary: ESMO Congress 2025 highlights progress in oncology.
More News
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- Most Exciting Prospects for 2026: AL Central
- Thursday: Invasions, Violations, and Abductions Across West Bank
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- Jon Stewart Finds Proof of Trump’s Planned 2028 Presidential Run
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Pashinyan's election campaign could lead to a split in Armenian society
- Israeli Colonizers Invade Bedouin Village Near Jerusalem
- Prime Minister Pashinyan should be excommunicated and arrested
- Uzbekistan pitches worldwide initiatives at UNESCO General Conference